Avalyn Pharma Inc. (AVLN)
$34.69-$1.82 (-4.98%) Today
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
No Form 4 activity for AVLN in the last 90 days.
14 Form 4 filings on record, the earliest from May 1, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Novo Holdings A/S | Other | Voting Common Stock | 3,327,734 | - | - | |
| Novo Holdings A/S | Other | Series A Preferred Stock | 18,000,000 | $0.00 | - | |
| Novo Holdings A/S | Other | Series B Preferred Stock | 1,986,369 | $0.00 | - | |
| Novo Holdings A/S | Open-market purchase | Voting Common Stock | 555,555 | $18.00 | $10.00M | |
| Novo Holdings A/S | Other | Series C-1 Preferred Stock | 25,899,284 | $0.00 | - | |
| Novo Holdings A/S | Other | Series C-2 Preferred Stock | 5,587,603 | $0.00 | - | |
| Novo Holdings A/S | Other | Series D Preferred Stock | 12,558,081 | $0.00 | - | |
| FMR LLC | Other | Common Stock | 727,585 | - | - | |
| FMR LLC | Other | Common Stock | 80,291 | - | - | |
| FMR LLC | Other | Common Stock | 872,868 | - | - | |
| FMR LLC | Other | Common Stock | 225,843 | - | - | |
| FMR LLC | Other | Common Stock | 377,948 | - | - | |
| FMR LLC | Other | Series A Preferred Stock | 727,585 | - | - | |
| FMR LLC | Other | Series B Preferred Stock | 80,291 | - | - | |
| FMR LLC | Other | Series C-1 Preferred Stock | 872,868 | - | - | |
| FMR LLC | Other | Series C-2 Preferred Stock | 225,843 | - | - | |
| FMR LLC | Other | Series D Preferred Stock | 377,948 | - | - | |
| Adam H. Golden - Officer | Grant or award | Stock Option (Right to Buy) | 254,891 | $0.00 | - | |
| Jill Carroll | Other | Common Stock | 1,419,298 | - | - | |
| Jill Carroll | Other | Common Stock | 489,486 | - | - | |
| Jill Carroll | Open-market purchase | Common Stock | 277,778 | $18.00 | $5.00M | |
| Jill Carroll | Other | Series C-1 Convertible Preferred Stock | 27,309,719 | - | - | |
| Jill Carroll | Other | Series D Convertible Preferred Stock | 9,418,561 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series D Convertible Preferred Stock | 9,418,560 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 1,419,298 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 489,486 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 489,486 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Open-market purchase | Common Stock | 277,778 | $18.00 | $5.00M | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 354,824 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Open-market purchase | Common Stock | 277,777 | $18.00 | $5.00M | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series C-1 Convertible Preferred Stock | 27,309,719 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series D Convertible Preferred Stock | 9,418,561 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series C-1 Convertible Preferred Stock | 6,827,429 | - | - | |
 Jon Congleton | Grant or award | Stock Option (Right to Buy) | 26,978 | $0.00 | - | |
 Heather D. Turner | Grant or award | Stock Option (Right to Buy) | 26,978 | $0.00 | - | |
 Melissa Rhodes - Officer | Grant or award | Stock Option (Right to Buy) | 211,975 | $0.00 | - | |
 Douglas R. Carlson - Officer | Grant or award | Stock Option (Right to Buy) | 211,975 | $0.00 | - | |
| Kate Haviland | Grant or award | Stock Option (Right to Buy) | 26,978 | $0.00 | - | |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | Other | Common Stock | 1,275,486 | - | - | |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | Other | Series C-1 Convertible Preferred Stock | 20,482,289 | $0.00 | - | |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | Other | Series D Convertible Preferred Stock | 4,060,259 | $0.00 | - | |
 Howard Lazarus - Officer | Grant or award | Stock Option (Right to Buy) | 211,975 | $0.00 | - | |
| Erin Lavelle | Grant or award | Stock Option (Right to Buy) | 26,978 | $0.00 | - | |
 Lyn Baranowski - Officer | Grant or award | Stock Option (Right to Buy) | 501,033 | $0.00 | - |
Avalyn Pharma Inc. (AVLN) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-05-05. The full record for AVLN runs to 14 Form 4 filings, the earliest from 2026-05-01. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of AVLN were filed in the last 90 days. 4 purchases are on record for this company.
No insider sales of AVLN were filed in the last 90 days.
This page tracks AVLN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add AVLN to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
